FOLLOW US

On November 2, 2022, Walgreens and CVS Pharmacy sent an offer of $10 billion in an effort to end all the opioid suits across the country. These lawsuits are centered around the pharmacies sale of controlled substances and prescription narcotics to its customers. Walgreens and CVS are two of the largest, most successful, and most well-known pharmacies in the United States. Each pharmacy has reportedly put up about $5 Billion in this offer, and there is even speculation that a third, Walmart will join in on the cause. It is unknown if Walmart will actually enter into this deal, as they have declined to speak on the matter. However, the speculation is that Walmart will put up its own $3 Billion for the cause.

If this deal were to go through, it would be monumental for all parties involved and would create a precedence unlike before. One of the lawyers for MDL made a statement: "These landmark agreements-in-principle reached with CVS and Walgreens on economic terms totaling more than $10 billion are an important step in our efforts to hold pharmacy defendants accountable for their role in the opioid epidemic that continues to devastate individual lives, as well as entire cities and states."

These cases stem from a universal frustration and desperation due to the opioid crisis in America. Increasing overdoes and deaths are continually linked to prescription pills and fentanyl. This along with the outrageous up-pricing of these prescriptions by the government. All around the country, people are desperate for a change in business practice. The prescription drug world is controlled by money and greed, and thousands of people are dying because of it.

In a statement, CVS would not admit that they've actually done anything wrong, and "Will continue to defend against any litigation that the final agreement does not resolve."

Walgreens also made a statement once the news broke that they would be involved in the deal: "This settlement framework is in the best interest of the company and our stakeholders at this time."

The MDL is In re: National Prescription Opiate Litigation, case number 1:17-md-02804, in the U.S. District Court for the Northern District of Ohio.